Rhythm Pharmaceuticals, Inc. (RYTM)

Market Cap	3.65B
Revenue (ttm)	112.53M
Net Income (ttm)	-261.57M
Shares Out	61.46M
EPS (ttm)	-4.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	370,513
Open	59.98
Previous Close	59.97
Day's Range	58.08 - 60.71
52-Week Range	31.53 - 68.58
Beta	2.09
Analysts	Strong Buy
Price Target	62.30 (+4.95%)
Earnings Date	Nov 5, 2024

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2017
• Employees: 226
• Stock Exchange: NASDAQ
• Ticker Symbol: RYTM
• Website: https://rhythmtx.com

Financial Performance

In 2023, Rhythm Pharmaceuticals's revenue was $77.43 million, an increase of 227.56% compared to the previous year's $23.64 million. Losses were -$184.68 million, 1.97% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price forecast is $62.3, which is an increase of 4.95% from the latest price.

Price Target

$62.3

(4.95% upside)

Analyst Consensus: Strong Buy